Chronic Mesenteric Ischemia Breath Testing
- Conditions
- Chronic Mesenteric Ischemia
- Interventions
- Drug: Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USADrug: U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USADiagnostic Test: Exercise + breath testDiagnostic Test: Breath test
- Registration Number
- NCT06022588
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Background and aims:
A gold standard diagnostic test to diagnose chronic mesenteric ischemia is currently lacking. Isotope labelled-butyrate and glucose breath testing could theoretically quantify mucosal oxygen consumption and thereby detect ischemia, since oxygen is needed to absorb and metabolize butyrate and glucose, and distinguish aerobic/anaerobic intestinal epithelial metabolism. Here we aim to test this notion and compare results to conventional biomarkers.
Methods:
Healthy volunteers were randomized into two control groups and two intervention groups, each consisting of five volunteers receiving either oral 13C -butyrate or 13C -glucose. The control groups performed breath tests without any physical exercise. The intervention groups performed a 30 minutes standardized bicycle exercise test, which has been proven to elicit mesenteric ischemia. Breath samples of expired 13CO2 were collected during a period of 4 hours and results were contrasted to measurements of biomarkers in peripheral blood.
- Detailed Description
Even as chronic mesenteric ischemia (CMI) is the most common vascular disorder involving the mesenteric arteries, accounting for 2% of all revascularization procedures, it remains an underdiagnosed condition. CMI is an invalidating disease that causes severe complaints of post-prandial abdominal pain, food fear and weight loss. Diagnosis of CMI remains difficult since no gold standard diagnostic test exists, the presumptive diagnosis of CMI is currently confirmed when a patient experiences relief of symptoms after revascularization. For making treatment decisions, clinicians rely on a consensus diagnosis, based on clinical history, presence of mesenteric artery stenosis on abdominal imaging, and, in dedicated centers, the outcome of a functional test, such as visible light spectroscopy (VLS) or tonometry. The diagnostic accuracy of this consensus diagnosis is unstatisfactory, since clinical improvement is achieved in only 73% of patients with a consensus diagnosis of CMI based on a single mesenteric artery stenosis. Per extenso in the remaining 27% treatment was initiated in patients not suffering from CMI. Stressing the need for a reliable diagnostic test to identify patients with CMI.
In the intestinal epithelium the most important substrate for mitochondrion-dependent ATP production, and by consequence as the source for CO2 release is butyrate, a small chain fatty acid produced by the intestinal microflora. Under ischemic conditions, butyrate can no longer be metabolized. The most straight forward biochemical pathway to cope with this situation is a switch in cellular metabolism to anaerobic glycolysis. In this process glucose is metabolized to pyruvate, producing two ATP molecules, providing an oxygen independent pathway for maintaining ATP production, but also resulting in the reduction of NAD+ molecules into NADH+. To maintain ATP production, pyruvate will undergo a process called fermentation resulting in the production of lactate in which NADH+ is recycled back to NAD+ so that glycolysis can continue. Upon subsequent transport via the blood, lactate is cleared in the liver and the resulting CO2 will leave the body via the lungs. Hence theoretically measuring the shift from butyrate towards glucose metabolism, which occurs in enterocytes under anaerobic conditions, could be a method to detect mucosal ischemia.
This multi-center randomized interventional proof of principal study explored the possibility to quantify mucosal oxygen content by labeled-butyrate and labelled-glucose breath testing as a potential test to diagnose CMI. Since both substrates are dependent on oxygen to be metabolized, it is expected that subjects with low mucosal oxygen concentrations will metabolize less butyrate and glucose compared to subjects with normal mucosal oxygen concentrations.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- healthy volunteers without any gastrointestinal complaints
- pregnant woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 13C -glucose control group Exercise + breath test 5 healthy volunteers performed the breath test without any psychical exercise 13C -butyrate control group Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA 5 healthy volunteers performed the breath test without any psychical exercise 13C -butyrate intervention group Exercise + breath test 5 healthy volunteers performed the breath test with psychical exercise - bicycle test 13C -glucose intervention group U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA 5 healthy volunteers performed the breath test with psychical exercise - bicycle test 13C -glucose control group U-13C6, 99%; Cambridge Isotope Laboratories, Inc.USA 5 healthy volunteers performed the breath test without any psychical exercise 13C -glucose intervention group Exercise + breath test 5 healthy volunteers performed the breath test with psychical exercise - bicycle test 13C -butyrate control group Breath test 5 healthy volunteers performed the breath test without any psychical exercise 13C -butyrate intervention group Sodium butyrate, 1-13C, 99%, Cambridge Isotope Laboratories, Inc.USA 5 healthy volunteers performed the breath test with psychical exercise - bicycle test
- Primary Outcome Measures
Name Time Method The median concentrations of measured 13CO2 At the following time points; baseline, 0.5, 1, 1.25 1.5, 1.75, 2, 2.25, 2.5, 3, 3.5 and 4 hours (total of 12 time points) after ingestion of 13C-butyrate or 13C-glucose. The median concentrations of measured 13CO2 at each time point where compared within the four groups and statistically tested with a Mann - Whitney U test.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Erasmus Medical Center - Department of Gastroenterology
🇳🇱Rotterdam, Netherlands